Cover Image
市場調查報告書

糖尿病視網膜病變的全球市場 (2015-2019年)

Global Diabetic Retinopathy Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 306326
出版日期 內容資訊 英文 84 Pages
訂單完成後即時交付
價格
Back to Top
糖尿病視網膜病變的全球市場 (2015-2019年) Global Diabetic Retinopathy Market 2015-2019
出版日期: 2015年05月13日 內容資訊: 英文 84 Pages
簡介

全球糖尿病視網膜病變的市場預計從2014年到2019年以6.89%的年複合成長率成長。

本報告提供全球糖尿病視網膜病變的治療所採用的藥物的市場相關調查、糖尿病視網膜病變概要、治療方法、主要的治療藥、各分子類型、投藥途徑、地區的市場規模的變化與預測、藥劑開發平台趨勢、市場的各種影響因素分析、競爭環境與市場佔有率,以及主要企業的簡介等彙整。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 產品概要
  • 產品簡介
    • Lucentis
    • Eylea

第4章 市場調查方法

第5章 簡介

第6章 疾病概要

  • 關於疾病
  • 病因
  • 診斷
  • 分類
  • 流行病學
  • 管理
    • 抗VEGF治療
    • 眼內類固醇注射
    • 雷射手術
    • 玻璃體切除手術

第7章 市場環境

  • 市場概要
  • 市場規模、預測
  • 要點
  • 波特的五力分析

第8章 產品研發線

第9章 各分子類型市場

  • 生物製藥
  • 皮質類固醇

第10章 各投藥途徑市場

  • 玻璃體內
  • 靜脈內

第11章 各地區市場

  • 南北美洲
    • 市場規模、預測
  • 歐洲、中東、非洲
    • 市場規模、預測
  • 亞太地區
    • 市場規模、預測

第12章 購買標準

第13章 市場促進因素

第14章 推進因素與其影響

第15章 市場課題

第16章 推進因素與課題的影響

第17章 市場趨勢

第18章 趨勢與其影響

第19章 供應商環境

  • 競爭模式
    • 主要消息
    • M&A
  • 市場佔有率分析
    • Novartis
    • F. Hoffmann-La Roche
    • Regeneron Pharmaceuticals
    • Bayer
  • 其他關注供應商

第20章 主要供應商分析

  • Bayer
  • F. Hoffmann-La Roche
  • Novartis
  • Regeneron Pharmaceuticals
    • 主要資料
    • 產業概要
    • 產品
    • 收益
    • 產業策略
    • SWOT分析等

第21章 相關報告

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR5881

About Diabetic Retinopathy

Diabetic retinopathy is a disorder of the eye that damages the blood vessels of the retina. The retina is the light-sensitive inner surface of the eye on which images are formed. Long-term diabetes affects the retina as high blood glucose levels can damage the tiny blood vessels in the retina. Diabetic retinopathy is broadly classified into non-proliferative diabetic retinopathy and proliferative retinopathy. Treatment for diabetic retinopathy depends on the stage of the disease and is directed toward slowing down or stopping the progression of the disease. Laser surgery, injection of corticosteroids or anti-VEGF drugs into the eye, and vitrectomy are some of the available treatments. One feature of diabetic retinopathy is diabetic macular edema. This is a serious medical condition involving leakage of fluid from the minute, delicate, and previously injured blood vessels located at the back of the eye, which then collects in the macula. This results in inflammation of tissue and blurry vision.

Technavio's analysts forecast the global diabetic retinopathy market to grow at a CAGR of 6.89% over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the global diabetic retinopathy market for the period 2015-2019. To calculate the market size, the report considers revenue from the sales of prescribed as well as off-label drugs available in the market.

The report also presents the vendor landscape and a corresponding detailed analysis of the four major vendors in the market. In addition, it discusses the major drivers that influence the growth and the challenges faced by the vendors and the market at large, as well as the key trends that contribute to the growth the market.

Technavio's report, Global Diabetic Retinopathy Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC; it also covers the global diabetic retinopathy market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Bayer
  • F. Hoffmann-La Roche
  • Novartis
  • Regeneron Pharmaceuticals

Other Prominent Vendors

  • Actavis
  • Alimera Sciences
  • Ampio Pharmaceuticals
  • Antisense Therapeutics
  • BCN Peptides
  • Boehringer Ingelheim
  • Glycadia
  • iCo Therapeutics
  • Isis Pharmaceuticals
  • Kowa Group
  • Lpath
  • Numoda Capital
  • Ohr Pharmaceutical
  • OPKO Health
  • Parexel International
  • Promedior
  • pSivida
  • Quark Pharmaceuticals
  • R-Tech Ueno
  • Sirnaomics
  • ThromboGenics

Market Driver

  • Growth in patient population
  • For a full, detailed list, view our report

Market Challenge

  • Availability of effective surgical treatments
  • For a full, detailed list, view our report

Market Trend

  • Launch of novel agents
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings
  • 03.3. Product Profiles
    • 03.3.1. Lucentis
    • 03.3.2. Eylea

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Disease Overview

  • 06.1. Understanding the Disease
  • 06.2. Etiology
    • 06.2.1. Elevated Blood Glucose
    • 06.2.2. Ischemia
    • 06.2.3. Hypoxia
    • 06.2.4. Neovascularization
    • 06.2.5. Increased Permeability of Retinal Vessels
  • 06.3. Diagnosis
    • 06.3.1. Retinal Photography
    • 06.3.2. Fluorescein Angiography
    • 06.3.3. Optical Coherence Tomography
  • 06.4. Classification
    • 06.4.1. Proliferative Diabetic Retinopathy
    • 06.4.2. Non-proliferative Diabetic Retinopathy
  • 06.5. Epidemiology
  • 06.6. Management
    • 06.6.1. Anti-VEGF Therapy
    • 06.6.2. Intraocular Steroid Injection
    • 06.6.3. Laser Surgery
    • 06.6.4. Vitrectomy

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Key Takeaways
  • 07.4. Five Forces Analysis

08. Pipeline Portfolio

09. Market Segmentation by Type of Molecule

  • 09.1. Biologics
  • 09.2. Corticosteroids

10. Market Segmentation by Route of Administration

  • 10.1. Intravitreal
  • 10.2. Intravenous

11. Geographical Segmentation

  • 11.1. Diabetic Retinopathy Market in Americas
    • 11.1.1. Market Size and Forecast
  • 11.2. Diabetic Retinopathy Market in EMEA
    • 11.2.1. Market Size and Forecast
  • 11.3. Diabetic Retinopathy Market in APAC
    • 11.3.1. Market Size and Forecast

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

  • 19.1. Competitive Scenario
    • 19.1.1. Key News
    • 19.1.2. Mergers and Acquisitions
  • 19.2. Market Share Analysis 2014
    • 19.2.1. Novartis
    • 19.2.2. F. Hoffmann-La Roche
    • 19.2.3. Regeneron Pharmaceuticals
    • 19.2.4. Bayer
  • 19.3. Other and Future Prominent Vendors

20. Key Vendor Analysis

  • 20.1. Bayer
    • 20.1.1. Key Facts
    • 20.1.2. Business Overview
    • 20.1.3. Business Segmentation by Revenue 2014
    • 20.1.4. Business Segmentation by Revenue 2013 and 2014
    • 20.1.5. Geographical Segmentation by Revenue 2014
    • 20.1.6. Business Strategy
    • 20.1.7. Recent Developments
    • 20.1.8. SWOT Analysis
  • 20.2. F. Hoffmann-La Roche
    • 20.2.1. Key Facts
    • 20.2.2. Business Overview
    • 20.2.3. Business Segmentation
    • 20.2.4. Business Segmentation by Revenue 2012 and 2013
    • 20.2.5. Sales by Geography
    • 20.2.6. Business Strategy
    • 20.2.7. Key Information
    • 20.2.8. SWOT Analysis
  • 20.3. Novartis
    • 20.3.1. Key Facts
    • 20.3.2. Business Description
    • 20.3.3. Business Segmentation
    • 20.3.4. Revenue by Business Segmentation
    • 20.3.5. Revenue Comparison 2012 and 2013
    • 20.3.6. Sales by Geography
    • 20.3.7. Business Strategy
    • 20.3.8. Key Developments
    • 20.3.9. SWOT Analysis
  • 20.4. Regeneron Pharmaceuticals
    • 20.4.1. Key Facts
    • 20.4.2. Business Overview
    • 20.4.3. Product Segmentation
    • 20.4.4. Revenue Product Segmentation
    • 20.4.5. Business Strategy
    • 20.4.6. Key Information
    • 20.4.7. SWOT Analysis

21. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Development of Diabetic Retinopathy
  • Exhibit 3: Classification of Diabetic Retinopathy
  • Exhibit 4: Snapshot of Global Diabetic Retinopathy Market
  • Exhibit 5: Global Diabetic Retinopathy Market 2014-2019 ($ millions)
  • Exhibit 6: Key Takeaways: Global Diabetic Retinopathy Market
  • Exhibit 7: Global Diabetic Retinopathy Market by Type of Molecule
  • Exhibit 8: Segmentation of Global Diabetic Retinopathy Market by Type of Molecule 2014
  • Exhibit 9: Global Diabetic Retinopathy Market by Route of Administration
  • Exhibit 10: Segmentation of Global Diabetic Retinopathy Market by Route of Administration 2014
  • Exhibit 11: Segmentation of Global Diabetic Retinopathy Market by Geography 2014
  • Exhibit 12: Segmentation of Global Diabetic Retinopathy Market by Geography 2019
  • Exhibit 13: Diabetic Retinopathy Market in Americas 2014-2019 ($ millions)
  • Exhibit 14: Diabetic Retinopathy Market in EMEA 2014-2019 ($ millions)
  • Exhibit 15: Diabetic Retinopathy Market in APAC 2014-2019 ($ millions)
  • Exhibit 16: Major Drivers of Global Diabetic Retinopathy Market
  • Exhibit 17: Major Challenges in Global Diabetic Retinopathy Market
  • Exhibit 18: Major Trends in Global Diabetic Retinopathy Market
  • Exhibit 19: Market Share Analysis of Vendors 2014
  • Exhibit 20: Global Diabetic Retinopathy Market: Revenue by Product 2014
  • Exhibit 21: Novartis: YoY Revenue and Growth Rate for Lucentis 2011-2014 ($ millions)
  • Exhibit 22: Key Takeaways: Novartis
  • Exhibit 23: F. Hoffmann-La Roche: YoY Revenue and Growth Rate for Lucentis 2011-2014 ($ millions)
  • Exhibit 24: Key Takeaways: F. Hoffmann-La Roche
  • Exhibit 25: Regeneron Pharmaceuticals: YoY Revenue and Growth Rate for Eylea 2011-2014 ($ millions)
  • Exhibit 26: Key Takeaways: Regeneron Pharmaceuticals
  • Exhibit 27: Bayer: YoY Revenue and Growth Rate for Eylea 2012-2014 ($ millions)
  • Exhibit 28: Key Takeaways: Bayer
  • Exhibit 29: Bayer: Business Segmentation by Revenue 2014
  • Exhibit 30: Bayer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
  • Exhibit 31: Bayer: Geographical Segmentation by Revenue 2014
  • Exhibit 32: Business Segmentation of F. Hoffmann-La Roche 2013
  • Exhibit 33: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013 ($ millions)
  • Exhibit 34: F. Hoffmann-La Roche: Pharmaceutical Sales by Geography 2013
  • Exhibit 35: F. Hoffmann-La Roche: Diagnostics Sales by Geography 2013
  • Exhibit 36: Novartis: Business Segmentation
  • Exhibit 37: Novartis: Revenue by Business Segmentation 2013
  • Exhibit 38: Novartis: Revenue by Business Segmentation 2012 and 2013 ($ millions)
  • Exhibit 39: Novartis: Revenue by Geographical Segmentation 2013
  • Exhibit 40: Regeneron Pharmaceuticals: Product Segmentation
  • Exhibit 41: Regeneron Pharmaceuticals: Revenue Product Segmentation 2013
Back to Top